News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
191,671 Results
Type
Article (8503)
Company Profile (10)
Press Release (183155)
Multimedia
Podcasts (11)
Webinars (4)
Section
Business (58004)
Career Advice (529)
Deals (10377)
Drug Delivery (26)
Drug Development (24572)
Employer Resources (31)
FDA (4279)
Job Trends (4431)
News (95103)
Policy (7389)
Tag
Academia (489)
Accelerated approval (15)
Adcomms (5)
Allergies (71)
Alliances (7279)
ALS (91)
Alzheimer's disease (581)
Antibody-drug conjugate (ADC) (207)
Approvals (4619)
Artificial intelligence (273)
Autoimmune disease (118)
Automation (23)
Bankruptcy (110)
Best Places to Work (3988)
BIOSECURE Act (3)
Biosimilars (106)
Biotechnology (12)
Bladder cancer (134)
Brain cancer (28)
Breast cancer (396)
Cancer (3001)
Cardiovascular disease (245)
Career advice (437)
Career pathing (3)
CAR-T (136)
CDC (7)
Cell therapy (360)
Cervical cancer (23)
Clinical research (23928)
Collaboration (846)
Company closure (1)
Compensation (553)
Complete response letters (26)
COVID-19 (740)
CRISPR (47)
C-suite (341)
Cystic fibrosis (53)
Data (4078)
Decentralized trials (1)
Depression (62)
Diabetes (254)
Diagnostics (2025)
Digital health (19)
Diversity (1)
Diversity, equity & inclusion (8)
Drug discovery (120)
Drug pricing (53)
Drug shortages (6)
Duchenne muscular dystrophy (118)
Earnings (48433)
Editorial (12)
Employer branding (5)
Employer resources (27)
Events (31310)
Executive appointments (430)
FDA (6050)
Fibrodysplasia Ossificans Progressiva (4)
Friedreich's ataxia (3)
Frontotemporal dementia (16)
Funding (739)
Gene editing (102)
Generative AI (17)
Gene therapy (293)
GLP-1 (467)
Government (1199)
Grass and pollen (5)
Guidances (352)
Healthcare (5295)
HIV (48)
Huntington's disease (16)
IgA nephropathy (44)
Immunology and inflammation (112)
Immuno-oncology (40)
Indications (81)
Infectious disease (897)
Inflammatory bowel disease (102)
Inflation Reduction Act (3)
Influenza (61)
Intellectual property (81)
Interviews (94)
IPO (6702)
IRA (8)
Job creations (715)
Job search strategy (382)
JPM (11)
Kidney cancer (16)
Labor market (32)
Layoffs (169)
Leadership (7)
Legal (1402)
Liver cancer (37)
Longevity (6)
Lung cancer (432)
Lymphoma (285)
Machine learning (24)
Management (10)
Manufacturing (298)
MASH (88)
Medical device (3828)
Medtech (3858)
Mergers & acquisitions (4190)
Metabolic disorders (687)
mRNA (37)
Multiple sclerosis (93)
NASH (7)
Neurodegenerative disease (167)
Neuropsychiatric disorders (51)
Neuroscience (1219)
NextGen: Class of 2026 (1414)
Non-profit (1055)
Now hiring (17)
Obesity (333)
Opinion (52)
Ovarian cancer (94)
Pain (94)
Pancreatic cancer (122)
Parkinson's disease (151)
Partnered (6)
Patents (146)
Patient recruitment (248)
Peanut (32)
People (6574)
Pharmaceutical (2)
Pharmacy benefit managers (10)
Phase 1 (6352)
Phase 2 (10059)
Phase 3 (9311)
Pipeline (4280)
Policy (40)
Postmarket research (954)
Preclinical (2119)
Press Release (12)
Prostate cancer (161)
Psychedelics (14)
Radiopharmaceuticals (101)
Rare diseases (453)
Real estate (921)
Recruiting (12)
Regulatory (6775)
Reports (17)
Research institute (473)
Resumes & cover letters (90)
Rett syndrome (28)
RNA editing (3)
RSV (54)
Schizophrenia (79)
Series A (110)
Series B (92)
Service/supplier (1)
Sickle cell disease (59)
Special edition (10)
Spinal muscular atrophy (76)
Sponsored (11)
Startups (601)
Stomach cancer (7)
Supply chain (43)
Tariffs (17)
The Weekly (10)
Vaccines (377)
Venture capital (46)
Weight loss (217)
Women's health (43)
Worklife (7)
Date
Today (62)
Last 7 days (294)
Last 30 days (1500)
Last 365 days (15695)
2026 (3472)
2025 (16153)
2024 (13654)
2023 (12586)
2022 (16376)
2021 (16028)
2020 (14213)
2019 (12463)
2018 (9248)
2017 (8431)
2016 (7674)
2015 (8968)
2014 (6474)
2013 (5020)
2012 (5583)
2011 (6090)
2010 (5121)
Location
Africa (199)
Alabama (20)
Alaska (2)
Arizona (71)
Arkansas (5)
Asia (11575)
Australia (1917)
California (6206)
Canada (1503)
China (576)
Colorado (241)
Connecticut (281)
Delaware (249)
Europe (28068)
Florida (703)
Georgia (183)
Hawaii (3)
Idaho (18)
Illinois (497)
India (29)
Indiana (257)
Iowa (8)
Japan (325)
Kansas (32)
Kentucky (22)
Louisiana (22)
Maine (33)
Maryland (578)
Massachusetts (4551)
Michigan (112)
Minnesota (301)
Mississippi (4)
Missouri (67)
Montana (9)
Nebraska (5)
Nevada (79)
New Hampshire (31)
New Jersey (1733)
New Mexico (8)
New York (1494)
North Carolina (628)
North Dakota (5)
Northern California (3100)
Ohio (165)
Oklahoma (5)
Oregon (9)
Pennsylvania (1024)
Puerto Rico (5)
Rhode Island (14)
South America (294)
South Carolina (10)
Southern California (2357)
Tennessee (87)
Texas (955)
United States (20868)
Utah (154)
Vermont (1)
Virginia (146)
Washington D.C. (18)
Washington State (455)
West Virginia (2)
Wisconsin (96)
191,671 Results for "7".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Digital Disruption in Life Sciences: L7 Informatics Says Competitive Advantage Will Come From Governed Execution
L7 Informatics CEO explains why the next wave of life sciences innovation depends on digital unified platforms that orchestrate workflows, contextualize data, and enable AI-actionable operations.
February 12, 2026
·
1 min read
Press Releases
Novo Nordisk A/S: Wegovy® HD (semaglutide 7.2 mg) approved in the US, providing 20.7% mean weight loss
March 19, 2026
·
5 min read
Mergers & acquisitions
Merck To Buy Terns, ‘Unprecedented’ Leukemia Drug for $6.7B as Keytruda Cliff Looms
Merck’s acquisition of Terns Pharmaceuticals follows other big-ticket purchases, including of Verona Pharma and Cidara Therapeutics, as the pharma prepares for the impending expiration of its blockbuster’s patents.
March 25, 2026
·
3 min read
·
Tristan Manalac
Job Trends
7 Key Insights Into the 2026 Job Market and Hiring Landscape
Biopharma professionals need to understand today’s job market and how they can stand out to position themselves for success. Three talent acquisition and recruiting experts discussed these topics in a
BioSpace
webinar, from the importance of contract work to the value of an advocate.
February 12, 2026
·
5 min read
·
Angela Gabriel
Press Releases
NextPoint Therapeutics Announces Clinical Entry of NPX372, a First-in-Class B7-H7–Targeted T Cell Engager to Treat Solid Tumors
February 10, 2026
·
2 min read
Press Releases
IDEAYA Biosciences Announces First-Patient-In for Phase 1 Trial of IDE034, a Potential First-In-Class B7H3/PTK7 Bispecific TOP1 ADC
February 25, 2026
·
5 min read
Mergers & acquisitions
Gilead Doubles Down on CAR T With $7.8B Arcellx Acquisition
The centerpiece of the takeover is anito-cel, a CAR T therapy under development for relapsed or refractory multiple myeloma. An FDA decision on the therapy is expected by December 2026.
February 23, 2026
·
2 min read
·
Tristan Manalac
Collaboration
Novartis Bets Up to $1.7B in Cardio-Focused Peptide Partnership
Novartis and Unnatural Products did not specify which disease targets they’re going after, only noting that the latter’s macrocyclic platform can generate potentially next-generation therapies that could apply to cardiovascular conditions.
February 19, 2026
·
2 min read
·
Tristan Manalac
Press Releases
Biocytogen Announces Clinical Milestone with First Patient Dosed in Phase 1 Trial of IDEAYA’s First-in-Class B7H3/PTK7 Bispecific TOP1 ADC IDE034
March 2, 2026
·
3 min read
Press Releases
Excalipoint Therapeutics Launches with $68.7 Million to Develop Next-Generation T-Cell Engager Therapies
March 18, 2026
·
6 min read
1 of 19,168
Next
